COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine are available for routine office visits. More Information-PLEASE CLICK HERE

Clinical Trial: 19247

Trial Status: Open
Disease Type: Multiple Myeloma
Trial ID 19247
Sponsor ID Janssen

A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

Principal Investigator
Mitul Gandhi, MD
5 Locations


Fairfax Office

Alexandria Office

Arlington Office

Gainesville Office

Loudoun Office

Learn More About This Trial
Other Relevant Trials
Trial ID D7900C00001
Sponsor ID

A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects with Relapsed/Refractory Multiple Myeloma

Principal Investigator
Mitul Gandhi, MD
Trial ID 19021
Sponsor ID Incye/IQVIA

A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma (INCB 01158-206)

Principal Investigator
Dipti Patel-Donnelly, MD